NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Sponsor
ClinicalTrials.gov Identifier: NCT05182073
Official Title: A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
First Posted: January 10, 2022
Click here for details on ClinicalTrials.gov
iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT576 (Code C186430)
CD16/IL-15RF-expressing CD38-eliminated Anti-BCMA CAR-iNK Cells FT576
FT 576
FT-576
FT576
iPSC-derived Anti-BCMA CAR-CD16-IL-15RF-expressing CD38-eliminated NKs FT576
iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated Natural Killer Cells FT576
iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT576
iPSC-derived CD16/IL-15RF-expressing CD38-eliminated Anti-BCMA CAR-NK Cells FT576
Drug: FT576 (Allogenic CAR NK cells with BCMA expression)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Daratumumab
Locations
United States, Alabama
United States, Colorado
United States, Indiana
United States, Tennessee
United States, Wisconsin